Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $166.00 at Wedbush

Neurocrine Biosciences (NASDAQ:NBIX) had its price objective boosted by Wedbush from $151.00 to $166.00 in a research note released on Tuesday,Benzinga reports. Wedbush currently has an outperform rating on the stock.

Other analysts have also issued research reports about the stock. Wells Fargo & Company reduced their price target on shares of Neurocrine Biosciences from $180.00 to $175.00 and set an “overweight” rating on the stock in a research report on Friday, February 13th. Wolfe Research assumed coverage on shares of Neurocrine Biosciences in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $160.00 target price on the stock. Truist Financial cut their target price on shares of Neurocrine Biosciences from $169.00 to $140.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Mizuho raised their target price on shares of Neurocrine Biosciences from $146.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, December 12th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Neurocrine Biosciences in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $180.70.

Neurocrine Biosciences Trading Down 1.2%

NASDAQ NBIX opened at $130.90 on Tuesday. The firm has a market capitalization of $13.14 billion, a price-to-earnings ratio of 28.09, a P/E/G ratio of 0.69 and a beta of 0.35. The firm’s 50 day simple moving average is $131.46 and its 200 day simple moving average is $138.91. Neurocrine Biosciences has a 1 year low of $84.23 and a 1 year high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.36 by ($0.48). The firm had revenue of $805.50 million for the quarter, compared to analyst estimates of $804.21 million. Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The business’s revenue was up 28.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.69 EPS. On average, equities research analysts forecast that Neurocrine Biosciences will post 4.28 earnings per share for the current year.

Insiders Place Their Bets

In other Neurocrine Biosciences news, CEO Kyle Gano sold 36,400 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $132.70, for a total value of $4,830,280.00. Following the sale, the chief executive officer owned 140,407 shares in the company, valued at $18,632,008.90. This trade represents a 20.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 4.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Neurocrine Biosciences

Large investors have recently modified their holdings of the business. USA Financial Formulas bought a new position in shares of Neurocrine Biosciences during the fourth quarter valued at $25,000. Golden State Wealth Management LLC raised its stake in shares of Neurocrine Biosciences by 120.5% during the third quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock valued at $26,000 after acquiring an additional 100 shares during the last quarter. Eastern Bank bought a new position in shares of Neurocrine Biosciences during the third quarter valued at $27,000. DJE Kapital AG bought a new position in shares of Neurocrine Biosciences during the fourth quarter valued at $28,000. Finally, Geneos Wealth Management Inc. raised its stake in shares of Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences News Summary

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Acquisition materially expands Neurocrine’s commercial footprint — adds VYKAT XR (first‑and‑only FDA‑approved therapy for hyperphagia in Prader‑Willi syndrome) and pushes the company into endocrinology/rare metabolic diseases, creating a multi‑product commercial platform alongside INGREZZA and CRENESSITY. Neurocrine Grows in Endocrinology, Rare Disease with $2.9B Soleno Buyout
• Positive Sentiment: Analysts reacted by lifting price targets and reiterating buys — multiple firms (Citigroup, Canaccord, HC Wainwright, BofA, Needham, Wedbush) raised targets substantially, signaling upside to consensus estimates and investor confidence in the deal’s revenue potential. Vykat XR Acquisition Unlocks Diversified Growth — TipRanks
• Neutral Sentiment: Market validated Soleno’s value — SLNO shares jumped sharply on the deal, confirming the premium paid by Neurocrine and market willingness to pay for VYKAT XR’s orphan indication. This supports deal rationale but doesn’t guarantee NBIX near‑term earnings upside. Soleno Therapeutics Soars 32% on $2.9B Merger
• Neutral Sentiment: Soleno voluntarily withdrew its European marketing application for VYKAT XR ahead of the takeover — Neurocrine says it will prioritize the U.S. launch. That could accelerate U.S. commercialization focus but delays/forgoes near‑term EU revenue. Soleno withdraws EU rare disease drug application — Reuters
• Negative Sentiment: Shares dropped on deal announcement — investors appear concerned about the price tag ($2.9B cash), near‑term dilution to capital flexibility or execution risks integrating a new therapeutic area while Neurocrine’s pipeline faces a near‑term lull. This immediate negative reaction drove today’s decline. This Pharma Stock Is Surging 40% — Barron’s
• Negative Sentiment: Some analysts caution on execution and orphan market risks — at least one firm (BMO) kept a Hold, highlighting integration and long‑term execution questions that could cap near‑term multiple expansion. Balanced View on Neurocrine — TipRanks

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.